Results 171 to 180 of about 29,410 (210)

Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. [PDF]

Circulation
Stepanian A, Travers RJ, Tesfu A, Wolter NL, Man JJ, Lu Q, Shamsuzzaman S, Deaton RA, Owens GK, Chen CS, Jaffe IZ.   +10 more
europepmc   +1 more source

Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence. [PDF]

Curr HIV/AIDS Rep
Mickens KL, Dillon SM, Guo K, Wilson CC, Santiago ML.   +4 more
europepmc   +1 more source

TNF-α Promotes the Recovery of Dorsal Root Ganglion Neurons from Cisplatin-Induced Injury Through an NGF-Independent Mechanism. [PDF]

Curr Issues Mol Biol
Wei Y, Xu X, Wu P, Chen X, Mo Q, Zhuo M.
europepmc   +1 more source

Erratum in: Functional Analyses of TNFR2 in Physiological and Pathological Retina Angiogenesis. [PDF]

Invest Ophthalmol Vis Sci
europepmc   +1 more source

Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases

Koh B, Gal Oz ST, Sato R, Nguyen HN, Dunlap G, Mahony C, Bolton C, Accelerating Medicines Partnership (AMP) RA/SLE Network, Wedderburn LR, Croft AP, Donlin L, Raychaudhuri S, Korsunsky I, Rao DA, Brenner MB.   +14 more
europepmc   +1 more source

The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy

Cells, 2022
The appreciation that cancer growth is promoted by a dynamic tumor microenvironment (TME) has spawned novel approaches to cancer treatment. New therapies include agents that activate quiescent T effector cells and agents that interfere with abnormal neovascularity.
Gumpei Yoshimatsu
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Abstract 5201: TNFR2 humanized mice: an ideal model for studying anti-TNFR2 antibodies

Cancer Research, 2023
Abstract Tumor necrosis factor (TNF) receptor 2 (TNFR2) is mainly expressed on the surface of regulatory T cells (Tregs) and CD8+ T cells, which can stimulate the proliferation of these cells through NF-kB activation. TNFR2 is also highly expressed on the surface of various human tumors, such as colorectal cancer and lung cancer ...
Huiyi Wang, Ying Li, Mingkun Zhang, Xu Su, Santi Suryani Chen, Zhiying Li, Mark Wade Moore, Jing Zhao, Xiang Gao, Cunxiang Ju   +9 more
openaire   +1 more source

Abstract 5050: Novel TNFR2 humanized mouse model for human TNFR2 antibody evaluation

Cancer Research, 2020
Abstract In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Tumor necrosis factor receptor 2 (TNFR2), also known as tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), is a transmembrane receptor that has been linked into immune modulation and tissue regeneration.
Yanan Guo, Yanan Li, Xiaofei Zhou, Youhong Su, Qingcong Lin   +4 more
openaire   +1 more source

TNFR2-targeting peptide for cancer immunotherapy

The Journal of Immunology, 2023
Abstract There is compelling evidence that tumor necrosis factor receptor type II (TNFR2) is preferentially expressed by highly immunosuppressive CD4+Foxp3+ regulatory T cells (Tregs), especially those present in tumor-infiltrating lymphocytes (TILs).
Xin Chen, Ping Liao, Zhonghao Chen
openaire   +1 more source